AstraZeneca购买EsoBiotec10亿美元,以扩大其癌症细胞治疗选择。 AstraZeneca buys EsoBiotec for up to $1 billion to expand its cancer cell therapy options.

AstraZeneca正在收购位于比利时的一家生物技术公司EsoBiotec, 耗资达10亿美元。 AstraZeneca is acquiring EsoBiotec, a Belgium-based biotech company, for up to $1 billion. EsoBiotec专门从事加强免疫系统抗癌能力的细胞疗法。 EsoBiotec specializes in cell therapies that enhance the immune system's ability to fight cancers. 利用EsoBiotec的ENABL平台, 扩大AstraZeneca的细胞治疗服务。 The acquisition aims to expand AstraZeneca's cell therapy offerings by leveraging EsoBiotec's ENaBL platform. 这项交易须经监管批准,预计将在2025年第二季度结束,使EsoBiotec成为AstraZenec的一个独资子公司。 The deal, subject to regulatory approvals, is expected to close by the second quarter of 2025, making EsoBiotec a wholly-owned subsidiary of AstraZeneca.